WeVote
Log In

Bill

Bill

S 1552

Relates to the establishment of reduced residential rates for electric and natural gas service to low-income customers

2025 Regular Session Introduced by Leroy Comrie and 3 co-sponsors

Adds pyruvate dehydrogenase complex deficiency to Massachusetts' newborn screening panel, enabling early diagnosis and follow-up care for affected infants.

REPORTED AND COMMITTED TO FINANCE
0
WeVote Research Nonpartisan
Bill Summary · S 1552

Summary — S.1552 (Massachusetts): Expand Newborn Screening Panel to Include Pyruvate Dehydrogenase Complex Deficiency

Status: Reported and committed to Finance (filed Jan 15, 2025; introduced May 1, 2025). Hearing scheduled July 14, 2025.

Purpose

S.1552 would amend Massachusetts General Laws, chapter 111, section 110A to add “pyruvate dehydrogenase complex deficiency” (PDH deficiency) to the list of conditions for which newborns must be screened. The intent is early identification of this metabolic disorder so affected infants can receive timely confirmatory testing, treatment, and follow‑up care.

Key change (text)

  • Amends Section 110A of chapter 111 by inserting after the word “cretinism” the phrase: “, pyruvate dehydrogenase complex deficiency”.

This is a narrow statutory change that adds PDH deficiency to the mandated newborn screening panel.

What PDH deficiency is (brief)

  • Pyruvate dehydrogenase (PDH) complex deficiency is an inherited metabolic disorder that impairs the body’s ability to convert pyruvate to acetyl‑CoA, often causing lactic acidosis and neurological impairment.
  • It is a rare condition; early diagnosis can enable interventions (dietary management such as ketogenic diet, vitamin supplementation like thiamine in some cases, supportive care, and specialist follow‑up) that may improve outcomes.

Immediate effects and implementation considerations

  • If enacted, the Department of Public Health (DPH) would include PDH deficiency among disorders for which routine newborn specimens are screened.
  • Implementation steps (not specified in the bill) would typically include: adopting or validating a screening assay, establishing confirmatory testing and reporting pathways, training clinical and laboratory staff, and updating parental notification and follow‑up protocols.
  • The bill text does not appropriate funding or specify timelines; therefore, costs (lab equipment, confirmatory testing, personnel, follow‑up services) and the schedule for operational rollout would be determined by DPH and the Legislature’s finance actions.

Who would be affected

  • Newborns born in Massachusetts (and their families), who would be screened for PDH deficiency as part of the routine newborn screening panel.
  • Hospitals, birthing centers, public health and clinical laboratories, pediatricians, metabolic/genetics clinics, and DPH programs responsible for newborn screening and follow‑up.
  • Potential fiscal impact to state public health labs and healthcare providers, depending on test complexity and volume.

Legislative status and timeline (as reported)

  • Filed: Jan 15, 2025 (Senate Docket No. 922)
  • Introduced (Senate reading): May 1, 2025; read twice and referred to Committee on Health, Education, Labor, and Pensions. A hearing was scheduled for July 14, 2025 (updated times noted).
  • Current status listed as “REPORTED AND COMMITTED TO FINANCE.”
  • Note: some docket entries provided with this bill record contain inconsistent committee names and sponsor lists that appear unrelated to this state bill. The principal sponsor in the bill text is Senator John F. Keenan (Norfolk and Plymouth). For official status and next steps, consult the Massachusetts Legislature’s website or the Senate Clerk’s office.

Fiscal/Policy notes

  • Statutory addition is small and targeted; fiscal effects depend on whether DPH can absorb testing within current newborn screening workflows or requires new resources.
  • Adding disorders to mandated panels typically triggers consideration by finance committees for appropriation, lab capacity planning, and guidelines for confirmatory testing and long‑term follow‑up.

For authoritative text and the latest status, refer to the Massachusetts Legislature docket for S.1552.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.